Phase 2 RCT | Single-dose Psilocybin for a treatment-resistant episode of major depression.

Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression – New England Journal of Medicine (link to abstract – $ for full-text)

Commentaries:

Largest trial to date shows that psilocybin reduces depression symptoms – King’s College London

Expert reaction to Phase IIb Clinical Trial of Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression – Science Media Centre

Related:

RCT | In patients with alcohol use disorder, the percentage of heavy drinking days was reduced with a psychedelic drug.

Phase 2 RCT: Psilocybin, a psychedelic compound, shows promise for the treatment of depression in a study with 59 patients

Research: “Magic mushrooms” for treatment-resistant depression

Commentary on Twitter

A single 25-mg dose of psilocybin was more effective than a 1-mg dose at alleviating treatment-resistant depression over a period of 3 weeks. The effect was attenuated at 12 weeks. https://t.co/sM1mISArvb pic.twitter.com/9YRaxfcpNT

— NEJM (@NEJM) November 2, 2022